{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T21:59:45Z","timestamp":1717797585472},"reference-count":28,"publisher":"FapUNIFESP (SciELO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:p>CONTEXT: Pharmacovigilance studies aim to detect, assess, understand and prevent risks of adverse effects of medications or any other possible drug related problem. Alpha interferon is being produced by Bio-Manguinhos\/Fiocruz, Rio de Janeiro, RJ, Brazil and used in the treatment of chronic hepatitis C at Brazilian National Health System. OBJECTIVE: To study the safety profile and effectiveness of alpha interferon in a sample of Brazilian patients with chronic hepatitis C genotypes 2 and 3, in Porto Alegre, RS, Brazil. METHOD: We followed a cohort of chronic hepatitis C genotypes 2 and 3 patients treated with alpha interferon plus ribavirin in a specialized outpatient clinic in southern Brazil. Adverse events were collected and classified according to severity in monthly structured interviews. To measure effectiveness, hepatitis C viral load was evaluated before, at the end and 24 weeks after the treatment. RESULTS: We followed 141 patients during the study period, of which 52.5% were female with mean age of 52 years. The most frequent adverse events were fatigue (84%), headache (79%) and myalgia (75%). There were 13 treatment interruptions due to adverse events, 9 of those considered serious adverse events. Virological response at end of treatment was 54.6% and after 24 weeks 39.7%, considering all patients who started treatment. CONCLUSION: The product produced by Bio-Manguinhos has similar efficacy and adverse event and sustained virological response profiles comparable to those found in the literature. This is the first study of pharmacovigilance performed with the Brazilian product. These data will be useful for planning and management of this disease in Brazil.<\/jats:p>","DOI":"10.1590\/s0004-28032012000200010","type":"journal-article","created":{"date-parts":[[2012,7,4]],"date-time":"2012-07-04T22:49:38Z","timestamp":1341442178000},"page":"150-156","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of alpha interferon (+ ribavirin) in the treatment of chronic viral hepatitis C genotypes 2 and 3 in a brazilian sample"],"prefix":"10.1590","volume":"49","author":[{"given":"Candice Beatriz Treter","family":"Gon\u00e7alves","sequence":"first","affiliation":[{"name":"HSP"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine Medeiros","family":"Amaral","sequence":"additional","affiliation":[{"name":"HSP"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme Becker","family":"Sander","sequence":"additional","affiliation":[{"name":"HSP"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norberto Luis Campos","family":"Martins","sequence":"additional","affiliation":[{"name":"HSP"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisandra","family":"Pereira","sequence":"additional","affiliation":[{"name":"HSP"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo Dornelles","family":"Picon","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande do Sul, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","first-page":"3","article-title":"The sustained response rates for chronic hepatitis C patients undergoing therapy with the several interferons and ribavarins supplied by Brazilians Health Ministry is comparable to those reported in the literature","volume":"41","author":"Acras RN","year":"2004","journal-title":"Arq Gastroenterol","ISSN":"http:\/\/id.crossref.org\/issn\/0004-2803","issn-type":"print"},{"key":"ref2","first-page":"227","article-title":"Interferon-alpha and ribavirin therapy on chronic hepatitis C v\u00edrus infection: the experience of Rio Grande do Sul State Health Department, Brazil","volume":"40","author":"Alves AV","year":"2003","journal-title":"Arq Gastroenterol","ISSN":"http:\/\/id.crossref.org\/issn\/0004-2803","issn-type":"print"},{"key":"ref3","first-page":"19","article-title":"Aten\u00e7\u00e3o farmac\u00eautica no Sistema \u00danico de Sa\u00fade: um exemplo de experi\u00eancia bem-sucedida com pacientes portadores de hepatite C","volume":"87","author":"Amaral KM","year":"2006","journal-title":"Rev Bras Farm","ISSN":"http:\/\/id.crossref.org\/issn\/0370-372X","issn-type":"print"},{"key":"ref4","series-title":"Dicion\u00e1rio de farmacoepidemiologia","first-page":"61","author":"B\u00e9gaud B","year":"1997"},{"key":"ref5","series-title":"Portaria n\u00b0 34, de 28 de setembro de 2007: Disp\u00f5e sobre protocolo cl\u00ednico e diretrizes terap\u00eauticas para hepatite viral C","year":"2007"},{"key":"ref6","series-title":"Portaria n\u00b0 221, de 13 de julho de 2011: Disp\u00f5e sobre protocolo cl\u00ednico e diretrizes terap\u00eauticas para hepatite viral C e coinfec\u00e7\u00f5es","year":"2011"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/hep.23531","article-title":"Identifying hepatitis C virus genotype 2\/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin","volume":"51","author":"Diago M","year":"2010","journal-title":"Hepatology","ISSN":"http:\/\/id.crossref.org\/issn\/0161-0538","issn-type":"print"},{"key":"ref8","series-title":"Micromedex healthcare series","year":"2007"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards IR","year":"2000","journal-title":"Lancet","ISSN":"http:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref10","series-title":"Farmacologia cl\u00ednica","first-page":"73","volume-title":"Rea\u00e7\u00f5es adversas a medicamentos","author":"Heineck I","year":"2004","edition":"3"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.amjmed.2005.01.073","article-title":"Treatment of hepatitis C","volume":"118","author":"Kim AI","year":"2005","journal-title":"Am J Med","ISSN":"http:\/\/id.crossref.org\/issn\/0002-9343","issn-type":"print"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ajh.2830490123","article-title":"Severe hyponatremia due to syndrome of inappropriate secretion of antidiuretic hormone in a patient receiving interferon-alpha for chronic myeloid leukemia","volume":"49","author":"Lei KI","year":"1995","journal-title":"Am J Hematol","ISSN":"http:\/\/id.crossref.org\/issn\/0361-8609","issn-type":"print"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/jhep.2001.26371","article-title":"A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C","volume":"34","author":"Lindsay KL","year":"2001","journal-title":"Hepatology","ISSN":"http:\/\/id.crossref.org\/issn\/0161-0538","issn-type":"print"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","volume":"339","author":"McHutchison JG","year":"1998","journal-title":"N Engl J Med","ISSN":"http:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref15","first-page":"1","article-title":"Consensus Statement on Management of Hepatitis C: 2002","volume":"19","year":"2002","journal-title":"NIH Consens State Sci Statements"},{"key":"ref16","series-title":"Protocolos cl\u00ednicos e diretrizes terap\u00eauticas: medicamentos excepcionais","author":"Picon PD","year":"2002"},{"key":"ref17","first-page":"259","article-title":"Implementation of Brazilian guidelines for treatment of hepatitis C: a cost-saving intervention in the South of Brazil","volume":"3","author":"Picon PD","year":"2005","journal-title":"Ital J Public Health"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","volume":"352","author":"Poynard T","year":"1998","journal-title":"Lancet","ISSN":"http:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref19","series-title":"Protocolos cl\u00ednicos e diretrizes terap\u00eauticas: medicamentos excepcionais","first-page":"431","volume-title":"Hepatite viral cr\u00f4nica C","author":"Sander GB","year":"2002"},{"key":"ref20","first-page":"507","article-title":"Interferon-alfa-2b plus ribavirin: a review of its use in the management of chronic hepatitis C","volume":"62","author":"Scott LJ","year":"2002","journal-title":"Drugs","ISSN":"http:\/\/id.crossref.org\/issn\/0012-6667","issn-type":"print"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4330","article-title":"Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review","volume":"4","author":"Shepherd J","year":"2000","journal-title":"Health Technol Assess","ISSN":"http:\/\/id.crossref.org\/issn\/1366-5278","issn-type":"print"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta8390","article-title":"Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation","volume":"8","author":"Shepherd J","year":"2004","journal-title":"Health Technol Assess","ISSN":"http:\/\/id.crossref.org\/issn\/1366-5278","issn-type":"print"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11110","article-title":"Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation","volume":"11","author":"Shepherd J","year":"2007","journal-title":"Health Technol Assess","ISSN":"http:\/\/id.crossref.org\/issn\/1366-5278","issn-type":"print"},{"key":"ref24","series-title":"Doen\u00e7as do f\u00edgado e do sistema biliar","first-page":"263","volume-title":"Hepatite pelo v\u00edrus C","author":"Sherlock S","year":"2004"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/bmj.329.7456.44","article-title":"Detection, verification and quantification of adverse drug reactions","volume":"329","author":"Stricker B","year":"2004","journal-title":"BMJ","ISSN":"http:\/\/id.crossref.org\/issn\/0959-8138","issn-type":"print"},{"key":"ref26","series-title":"Definitions","year":"2001"},{"key":"ref27","series-title":"The importance of pharmacovigilance: safety monitoring of medicinal products","year":"2002"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1046\/j.1365-2036.2003.01747.x","article-title":"Systematic review: peginterferon vs standard interferon in the treatment of chronic hepatitis C","volume":"18","author":"Zaman A","year":"2003","journal-title":"Aliment Pharmacol Ther","ISSN":"http:\/\/id.crossref.org\/issn\/0269-2813","issn-type":"print"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ag\/v49n2\/10.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,30]],"date-time":"2019-06-30T14:33:25Z","timestamp":1561905205000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032012000200010&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0004-28032012000200010"],"URL":"https:\/\/doi.org\/10.1590\/s0004-28032012000200010","relation":{},"ISSN":["0004-2803"],"issn-type":[{"value":"0004-2803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}